From the leaves of Globularia alypum , three new phenylethyl glycosides, namely galypumosides A (=2‐(3,4‐dihydroxyphenyl)ethyl O ‐ α ‐rhamnopyranosyl‐(1→3)‐4‐ O ‐[( E )‐caffeoyl]‐6‐ O ‐[( E )‐ p ‐coumaroyl]‐ β ‐glucopyranoside; 1 ), B (=2‐(3,4‐dihydroxyphenyl)ethyl O ‐ α ‐rhamnopyranosyl‐(1→3)‐4‐ O ‐[( E )‐caffeoyl]‐6‐ O ‐[( E )‐feruloyl]‐ β ‐glucopyranoside; 2 ), and C (=2‐(3,4‐dihydroxyphenyl)ethyl O ‐ α ‐rhamnopyranosyl‐(1→3)‐4‐ O ‐[( E )‐caffeoyl]‐6‐ O ‐menthiafoloyl‐ β ‐glucopyranoside; 3 ), were isolated, together with two known phenylethyl glycosides, calceolarioside A and verbascoside. Eight iridoid glucosides, catalpol, globularicisin, globularin, globularidin, globularinin, globularimin, lytanthosalin, and alpinoside, a flavon glycoside, 6‐hydroxyluteolin 7‐ O ‐sophoroside, a lignan glycoside, syringaresinol 4′‐ O ‐ β ‐glucopyranoside, and a phenylpropanoid glycoside, syringin, were also obtained and characterized. The structures of the isolates were elucidated on the basis of 1D‐ and 2D‐NMR experiments as well as HR‐MALDI‐MS.
No takes yet. Share an insight, caveat, or question.
Kırmızıbekmez et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: